Literature DB >> 16192494

JAK2 mutations in myeloproliferative disorders.

Ayalew Tefferi, Terra L Lasho, Gary Gilliland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16192494     DOI： 10.1056/NEJMc051878

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  20 in total

1.  Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis.

Authors:  Marla Lay; Rajan Mariappan; Jason Gotlib; Lisa Dietz; Siby Sebastian; Iris Schrijver; James L Zehnder
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

2.  Histone modifiers in cancer: friends or foes?

Authors:  Idan Cohen; Elżbieta Poręba; Kinga Kamieniarz; Robert Schneider
Journal:  Genes Cancer       Date:  2011-06

3.  Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling.

Authors:  Matthew A Held; Emily Greenfest-Allen; Su Su; Christian J Stoeckert; Matthew P Stokes; Don M Wojchowski
Journal:  Cell Signal       Date:  2020-02-03       Impact factor: 4.315

4.  In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.

Authors:  Amos Gaikwad; Roberto Nussenzveig; Enli Liu; Stephen Gottshalk; KoTung Chang; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-04       Impact factor: 3.084

5.  Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.

Authors:  Brady L Stein; Donna M Williams; Ophelia Rogers; Mary Ann Isaacs; Jerry L Spivak; Alison R Moliterno
Journal:  Exp Hematol       Date:  2010-10-01       Impact factor: 3.084

Review 6.  Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types.

Authors:  Zhaohui Ye; Linzhao Cheng
Journal:  Regen Med       Date:  2010-07       Impact factor: 3.806

7.  Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia.

Authors:  Andrea Hoelbl; Christian Schuster; Boris Kovacic; Bingmei Zhu; Mark Wickre; Maria A Hoelzl; Sabine Fajmann; Florian Grebien; Wolfgang Warsch; Gabriele Stengl; Lothar Hennighausen; Valeria Poli; Hartmut Beug; Richard Moriggl; Veronika Sexl
Journal:  EMBO Mol Med       Date:  2010-03       Impact factor: 12.137

8.  Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.

Authors:  Ulrike Bacher; Svetlana Asenova; Anita Badbaran; Axel Rolf Zander; Haefaa Alchalby; Boris Fehse; Nicolaus Kröger; Claudia Lange; Francis Ayuk
Journal:  Clin Exp Med       Date:  2009-07-23       Impact factor: 3.984

9.  Molecular mechanisms of uterine leiomyosarcomas: involvement of defect in LMP2 expression.

Authors:  Takuma Hayashi; Yuto Shimamura; Taro Saegusa; Akiko Horiuchi; Yukihiro Kobayashi; Nobuyoshi Hiraoka; Yae Kanai; Hiroyuki Aburatani; Kenji Sano; Ikuo Konishi
Journal:  Gene Regul Syst Bio       Date:  2008-07-22

Review 10.  Human growth disorders associated with impaired GH action: Defects in STAT5B and JAK2.

Authors:  Vivian Hwa
Journal:  Mol Cell Endocrinol       Date:  2020-10-27       Impact factor: 4.102
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.